孟鲁司特钠联合糠酸莫米松鼻喷雾剂治疗变应性鼻炎的临床疗效

Clinical efficacy of montelukast sodium combined with mometasone furoate aqueous nasal spray in the treatment of allergic rhinitis

目的探讨孟鲁司特钠联合糠酸莫米松鼻喷雾剂治疗变应性鼻炎的临床疗效。方法选取宁乡市人民医院2018年3月—2020年5月收治的变应性鼻炎患者80例,按照随机抽取法分为对照组和试验组,各40例。对照组予以糠酸莫米松鼻喷雾剂治疗,试验组在对照组基础上予以孟鲁司特钠治疗。2组均治疗8周。比较2组临床疗效,治疗前后血清细胞因子〔包括白介素4(IL-4)、白介素8(IL-8)以及干扰素γ(IFN-γ)〕、T淋巴细胞亚群(包括CD_(4)^(+)细胞分数、CD_(8)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值),并观察2组不良反应发生情况。结果试验组总有效率高于对照组(P<0.05)。治疗前2组IL-4、IL-8、IFN-γ比较,差异无统计学意义(P>0.05);治疗后试验组IL-4、IL-8低于对照组,IFN-γ高于对照组(P<0.05)。治疗前2组CD_(4)^(+)细胞分数、CD_(8)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值比较,差异无统计学意义(P>0.05);治疗后试验组CD_(4)^(+)细胞分数、CD_(8)^(+)细胞分数、CD_(4)^(+)/CD_(8)^(+)细胞比值高于对照组(P<0.05)。2组均未发生严重不良反应。结论孟鲁司特钠联合糠酸莫米松鼻喷雾剂治疗变应性鼻炎的临床疗效确切,可有效改善患者临床症状,抑制炎性反应,提升T淋巴细胞亚群,且安全性较高。

To investigate the clinical efficacy of montelukast sodium combined with mometasone furoate aqueous nasal spray in the treatment of allergic rhinitis.Methods A total of 100 cases of patients with allergic rhinitis were selected from March 2018 to May 2020 in Ningxiang People's Hospital,which were randomly divided into control group and experimental group,with 40 cases in each group.The control group was treated with mometasone furoate aqueous nasal spray,the experimental group was treated with montelukast sodium on the basis of the control group.Both groups were treated for 8 weeks.Clinical efficacy,serum cytokines(including IL-4,IL-8 and IFN-γ),T lymphocyte subsets(including CD_(4)^(+)cell fraction,CD_(8)^(+)cell fraction and CD_(4)^(+)/CD_(8)^(+)cell ratio)before and after treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of the experimental group was higher than control group(P<0.05).Before treatment,there was no significant difference in IL-4,IL-8 and IFN-γbetween the two groups(P>0.05);after treatment,the experimental group of IL-4 and IL-8 were lower than control group,and IFN-γwas higher than control group(P<0.05).Before treatment,there was no significant difference in CD_(4)^(+)cell fraction,CD_(8)^(+)cell fraction and CD_(4)^(+)/CD_(8)^(+)cell ratio between the two groups(P>0.05);after treatment,CD_(4)^(+)cell fraction,CD_(8)^(+)cell fraction and CD_(4)^(+)/CD_(8)^(+)cell ratio in experimental group were higher than those in control group(P<0.05).No serious adverse reactions occurred in both groups.Conclusion Montelukast sodium combined with mometasone furoate aqueous nasal spray have an exact clinical effect for allergic rhinitis,which can effectively improve the clinical symptoms of patients,inhibit inflammatory reaction and increase T lymphocyte subsets,and with high safety.